DPA
TVRD

Devon Park Associates’s Tvardi Therapeutics TVRD Stock Holding History

Devon Park Associates’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-16,558
Closed -$5.99M – 4
2015
Q1 		$5.99M Sell
16,558
-15,439
-48% -$5.84M 4.41% 3
2014
Q4 		$11.5M Buy
+31,997
New +$10.3M 8.76% 2

Other funds holding TVRD

RCP
Rho Capital Partners New York $20.4M AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
CPM
Chesapeake Partners Management Baltimore, Maryland $669M AUM 1.23% 1-Year Est. Return
WSA
Wall Street Associates Lajolla, California $151M AUM 30.3% 1-Year Est. Return
TAM
Tiverton Asset Management Wilimington, Delaware $2.88B AUM 5.6% 1-Year Est. Return
EAM
EverPoint Asset Management Stamford, Connecticut $5.38B AUM 21.45% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Devon Park Associates's TVRD Position: Q2 2015 in Review

Devon Park Associates sold out of Tvardi Therapeutics (TVRD) in Q2 2015, closing a stake of 16,558 shares — an estimated $5.99M sold.

Devon Park Associates first reported a position in TVRD in Q4 2014 and held it in 2 quarters. The position peaked at $11.5M in Q4 2014. 75 funds tracked by Wall St. Rank hold TVRD as of Q2 2015.

  • Devon Park Associates reported no remaining Tvardi Therapeutics position as of Q2 2015 after selling out during the quarter.
  • Devon Park Associates sold 16,558 Tvardi Therapeutics shares in Q2 2015, an estimated $5.99M.
  • Devon Park Associates first reported a position in Tvardi Therapeutics in Q4 2014 and held it in 2 quarters.
  • Devon Park Associates's Tvardi Therapeutics position peaked at $11.5M in Q4 2014.
  • 75 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q2 2015.

Based on Devon Park Associates's 13F filing for Q2 2015, filed 14 Aug 2015.